Travere Therapeutics Inc (NAS:TVTX)
$ 6.16 -0.18 (-2.84%) Market Cap: 468.95 Mil Enterprise Value: 431.93 Mil PE Ratio: 0 PB Ratio: 6.33 GF Score: 54/100

Retrophin Inc at Barclays Global Healthcare Conference Transcript

Mar 14, 2019 / 05:35PM GMT
Release Date Price: $22.5 (-2.17%)
Scott Daniel Puckhaber
Barclays Bank PLC, Research Division - Research Analyst

All right, we'll get started. I'm Scott Puckhaber, I'm the biopharmaceutical team here at Barclays. It's my pleasure to introduce Retrophin. And today, we have CEO, Eric Dube, with us.

So Eric, do you want to come up?

Eric M. Dube
Retrophin, Inc. - President, CEO & Director

Thank you, Scott, and good afternoon, everyone, and thank you to Barclays for the opportunity to share an update on Retrophin with you today.

In my presentation, I'll be sharing some forward-looking statements, so you can look at our SEC filings for additional information.

I joined the company the beginning of this year, and I am proud to represent the over 200 employees at Retrophin who make it their life's work to identify, develop and deliver life-changing therapies for patients living with rare disease. And today, I'd like to share a little bit about the company and focus particularly on our pipeline. I believe that Retrophin offers a unique profile for a rare disease

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot